Results After the introduction of more directed therapy, there was stabilization of the patient's condition over the next nine years while under bisphosphonate treatment, followed by a switch to RANK ligand inhibitor therapy and later bisphosphonate treatment again. This was made evident through ...
In this case report, we present a patient with genetically confirmed MCTO who early in the course of the disease presented with generalized highbone turnover. He was treated withdenosumab, a human monoclonal RANKL inhibitor, which stabilized the osteoporosis and may have arrested further osteolysis...
We further proved that the activation of NF-κB is crucial for RANKL/RANK signaling to regulate dγδ T polarization with the help of PDTC, a selective inhibitor of NF-κB. As shown in Fig. 5c, d, increased levels of TGF-β1 production and Foxp3 expression in dγδ T, which was co...
Oncology: Orally administered RANKL inhibitor promising for treating bone metastasis Tumor cells colonized in bone can induce expression of a protein called receptor activator of nuclear factor kappa-Β ligand (RANKL), and an orally administered RANKL inhibitor is a promising therapeutic strategy for tre...
Proteins were extracted from femur bone tissues utilizing Tris lysis buffer/protease inhibitor cocktail (Biospes, China) and the total protein concentration was determined according to Bradford method [38]. Samples (50 µg total protein) were separated by gel electrophoresis and transferred to PVDF...
Alendronate sodium (AS), an aminobisphosphonate bone resorption inhibitor, might suppress OCs’ activity, decrease bone turnover, augment bone density, and enhance bone strength via the NF-κB and MAPK pathways [23,24]. Nevertheless, prolonged administration of AS could elicit gastrointestinal ...